EPS for Savara Inc. (SVRA) Expected At $-0.34

July 13, 2018 - By Robert Reynolds

Analysts expect Savara Inc. (NASDAQ:SVRA) to report $-0.34 EPS on August, 8.They anticipate $0.56 EPS change or 62.22 % from last quarter’s $-0.9 EPS. After having $-0.32 EPS previously, Savara Inc.’s analysts see 6.25 % EPS growth. The stock increased 0.39% or $0.05 during the last trading session, reaching $12.72. About 93,874 shares traded. Savara Inc. (NASDAQ:SVRA) has risen 73.10% since July 13, 2017 and is uptrending. It has outperformed by 60.53% the S&P500.

Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company has market cap of $392.24 million. The Company’s product pipeline comprises AeroVanc, a Phase III ready inhaled formulation of vancomycin for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, a Phase II/III stage inhaled granulocyte-macrophage colony-stimulating factor for the treatment of autoimmune pulmonary alveolar proteinosis; and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction. It currently has negative earnings.

Another recent and important Savara Inc. (NASDAQ:SVRA) news was published by Globenewswire.com which published an article titled: “Savara Joins Russell 3000® Index” on June 25, 2018.

Savara Inc. (NASDAQ:SVRA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.